Comparative Pharmacology
Head-to-head clinical analysis: HADLIMA versus HUMIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HADLIMA versus HUMIRA.
HADLIMA vs HUMIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNF-alpha) and neutralizes its biological activity by blocking its interaction with the p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNF, including changes in adhesion molecules and apoptosis.
Tumor necrosis factor alpha (TNF-α) inhibitor; a recombinant human IgG1 monoclonal antibody that binds to soluble and membrane-bound TNF-α, preventing its interaction with p55 and p75 TNF receptors, thereby reducing inflammation and immune activation.
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
Adult: 40 mg subcutaneously every other week. For ulcerative colitis: initial dose 160 mg on day 1, then 80 mg on day 15, then 40 mg every other week starting day 29.
None Documented
None Documented
Terminal elimination half-life approximately 2 weeks (12-16 days); supports every-2-week dosing in maintenance therapy.
Terminal elimination half-life is approximately 14 days (range 10–20 days) in adults, supporting a subcutaneous dosing interval of every 2 weeks. Longer half-life in older patients.
Renal: 0.1-0.5% as unchanged drug in urine; biliary/fecal: 70-90% as metabolites; mostly via reticuloendothelial system degradation.
Adalimumab is primarily eliminated via reticuloendothelial system degradation; no significant renal or biliary excretion. <1% excreted unchanged in urine.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor